FdaApplication
NDA 213498
Identifiers
- fda_app_no: NDA213498
Properties
| Property | Value |
|---|---|
| applicant_name | VANDA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2021-03-18 |
Revenue by product
PONVORY
| Period | Revenue |
|---|---|
| Q2 2026 | $7.9M |
| Q1 2026 | $6.2M |
| Q4 2025 | $7.6M |
| Q3 2025 | $7.0M |
| Q2 2025 | $7.1M |
| Q1 2025 | $5.6M |
| Q4 2024 | $6.5M |
| Q3 2024 | $5.9M |
| Q2 2024 | $8.6M |
| Q1 2024 | $6.8M |
| Q4 2023 | $1.6M |
| Q3 2023 | $0.0M |
| Q2 2023 | $0.0M |
| Q1 2023 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (10)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PONVORY | PONESIMOD | 3MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 20MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 8MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 4MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 2MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 6MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 7MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 5MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 10MG | TABLET;ORAL |
| PONVORY | PONESIMOD | 9MG | TABLET;ORAL |
10 products